Angel Biotech Share Price (ABH)

You missed the end part, its abh who provide the ctx cells

Guildford, UK, 8 September 2010: ReNeuron Group plc (LSE: RENE.L) gives a trading update ahead of its 2010 Annual General Meeting which will take place today at 10.00am (BST) at the offices of Morrison & Foerster, City Point, One Ropemaker Street, London, EC2Y 9AW. In the Company's preliminary results statement on 29 June, we announced that the PISCES (Pilot Investigation of Stem Cells in Stroke) clinical trial with our ReN001 stem cell therapy had received local site approvals in Scotland, enabling the commencement of patient recruitment for the trial. We are pleased to report that the trial has attracted a high level of interest from disabled stroke patients from the local Glasgow community and beyond. As a result, the clinical team, led by Professor Keith Muir, has been able to progress the selection of initial patients meeting the eligibility requirements for the trial. Given the complexities of the PISCES trial and the highly novel nature of the ReN001 therapy, we are greatly encouraged by this progress. Assuming a successful pre-treatment evaluation period once enrolled, we maintain our expectation of initial patient dosing in the PISCES trial towards the end of the year. http://www.reuters.com/article/idUS47052+08-Sep-2010+RNS20100908

any reason for the drop?

i can't believe this...

Marketing hype no substance sometimes. Hope exposure here will lead to a positive development in a tough market. Pharmas take no prisoners; so we will see. TWT (Time will tell)

spot on post all makes sense harper very good at keeping the hook baited